+8.47% for Monopar Therapeutics stock as buyers push price above key averages

Traders Union
All News
Financial News
Monopar Therapeutics jumps 8.47% today

Highlights

MNPR/USD maintains strong bullish momentum across all timeframes, supported by continued buying activity and elevated volatility.
Current technical indicators show overbought conditions, suggesting the potential for short-term consolidation despite prevailing upward trend.
Price is forecast to trade between $82.53 and $106.33, with immediate support at $88.90 and low probability of a downside move.

Overbought signals persist as buying momentum extends above technical support

On the technical side, MNPR is trading above the MA-20 and MA-50 on the working timeframe, as well as the MA-200 on the daily chart. The Ichimoku Kijun level at $88.895 is acting as immediate support. Technical indicators show robust buying pressure: both the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) indicate continued momentum, while the Relative Strength Index (RSI) is in buy territory. Bull/Bear Power and Commodity Channel Index (CCI) both reflect overbought conditions along with active buyer dominance, though the Stochastic RSI remains neutral. The Awesome Oscillator aligns with the ongoing upward swing.

Upside continuation favored as volatility shapes short-term trading range

In the near term, MNPR is forecast to trade within a range between $82.5274 and $106.3326, reflecting typical volatility for the stock. The probability of a continued up move is very high, with downside risk considered minimal. Should the price break above resistance, bullish continuation could follow; a drop below the immediate support at the Kijun level would increase the risk of a corrective move. If prices remain within this band, sideways consolidation may emerge in the coming sessions.

Viktoras Karapetjanc, expert at Traders Union, sees strong momentum for Monopar Therapeutics as the stock trades above all key moving averages and hovers near session highs. He notes that technical signals point to robust buyer interest and a bullish setup, with $88.895 now acting as immediate support. The analyst believes the probability of further gains is high, with volatility likely to continue within the projected range. In his words: "Price action and technical indicators support a positive outlook — as long as $88.895 holds, I expect bulls to remain in control."

Earlier, analysts noted that Monopar Therapeutics was exhibiting strong bullish momentum driven by technical strength and regulatory progress. With the stock now extending gains and multiple overbought signals persisting, traders should be alert for a potential momentum shift if the stock fails to break above resistance in the coming sessions.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.